Trial Profile
Efficacy of switching from a combination therapy of long-acting somatostatin analogs (LA-SSAs) and pegvisomant to weekly pegvisomant in acromegaly patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2016
Price :
$35
*
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- 13 Oct 2016 New trial record